The role of platelet receptors and adhesion molecules in coronary artery disease

Coronary Artery Disease

Volumn 14, Issue 1, 2003, Pages 65-79

  Samara, Waiel M ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Acute coronary syndrome; Platelet activation; Platelet adhesion; Platelet aggregation; Platelet receptors; Platelet leucocyte interactions

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; CLOPIDOGREL; COLLAGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRONECTIN; FIBRONECTIN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN VI; HEPARIN; HIRUDIN; HIRULOG; INTEGRIN; LAMIFIBAN; LAMININ RECEPTOR; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR; THROMBIN RECEPTOR; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE RECEPTOR; THROMBOSPONDIN; THROMBOXANE A2; TIROFIBAN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CELL ACTIVITY; CELL INTERACTION; CELL STRUCTURE; CELL TYPE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LEUKOCYTE; MOLECULAR INTERACTION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; RECEPTOR OCCUPANCY; RESTENOSIS; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANTIGENS, CD31; CD40 LIGAND; CORONARY DISEASE; HUMANS; INTEGRINS; MEMBRANE GLYCOPROTEINS; MYOCARDIAL INFARCTION; P-SELECTIN; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, FIBRINOGEN; RECEPTORS, LAMININ; RECEPTORS, THROMBIN; THROMBOLYTIC THERAPY;

EID: 0037296525     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200302000-00008     Document Type: Review

References (193)

1. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000; 342:101-114.
2. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28:1643-1651.
3. Timpl R. Structure and biological function of basement membrane protein. Eur J Biochem 1989; 180:487-502.
4. Beck K, Hunter I, Engel J. Structure and function of laminin: anatomy of a multidomain glycoprotein. FASEB J 1990; 4:148-160.
5. Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature 1988; 336:487-489.
6. ++ ions, shear rate, and platelet membrane glycoproteins. Blood 1992; 79:928-935.
7. Polanowska-Grabowska R, Simon CG Jr, Gear AR. Platelet adhesion to collagen type I, collagen type IV, vWF, fibronectin, laminin and fibrinogen: rapid kinetics under shear. Thromb Haemost 1999; 81:118-123.
8. Jll CR, Engvall E, Ruoslahti E. Adhesion of platelets to laminin in the absence of activation. J Cell Biol 1984; 99:2140-2145.
9. Mosher DF. Fibronectin. San Diego, California: Academic Press; 1989.
10. Hynes RO. Fibronectins. New York: Springer; 1989.
11. Piotrowicz RS, Orchekowski RP, Nugent DJ, Yamada KY, Kumicki TJ. GP Ic-IIa functions as an activation-independent fibronectin receptor on human platelets. J Cell Biol 1988; 106:1359-1364.
12. Lopez JA. The platelet GP Ib/IX complex. Blcod Coagul Fibrinol 1994; 5:97-119.
13. Rand HJ, Glanville RW, Wu XX, Ross JM, Zangari M, Gordon RE, et al. The significance of subendothelial von Willebrand factor. Thromb Haemost 1997; 78:445-450.
14. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL, et al. Shear induced platelet aggregation requires vWF and platelet membrane GP Ib and GP IIb/IIIa. Blood 1987; 69:625-628.
15. Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors: a dual role for GP IIb/IIIa mediated by fibrinogen and GP Ib-vWF. J Biol Chem 1992; 267:11300-11306.
16. Nichols TC, Bellinger DA, Reddick RL, Read MS, Koch GG, Brimkhous K, et al. Role of vWF in arterial thrombosis. Circulation 1991; 83(suppl 6):IV56-64.
17. Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, et al. Blockade of platelet membrane GP Ib receptors delays intracoronary thrombogenesis, enhances thombolysis, and delays coronary artery re-occlusion in dogs. Circulation 1994; 89:2822-2828.
18. Jansson JH, Nilsson TK, Johnson O. vWF in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66:351-355.
19. Thompson SG, Kienast J, Pyke SD, Haverkate F, Van De Loo J, et al. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-641.
20. Gonzales-Conejero R, Lozano ML, Rivera J, Corral J, Imiesta J, Moraleda J. Polymorphisms of platelet membrane GP Ib alpha associated with arterial thrombotic disease. Blood 1998; 92:2771-2776.
21. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86:189-197.
22. Sixma JJ, Van Zanten GH, Huizinga EG, Van Der Plas RM, Verkley M, Wu YP, et al. Platelet adhesion: an update. Thromb Haemost 1997; 78:434-438.
23. Kainoh M, Ikeda Y, Nishio S, Nakadate T. GP Ia/IIa-mediated activation-dependent platelet adhesion to collagen. Thromb Res 1992; 65:165-176.
24. Takashi N, Jun-ichi K, Minoru O, Narendra NT. Activation of GP IIb/IIIa induced by platelet adhesion to collagen is mediated by both alpha 2 beta 1 integrin and GP VI. J Biol Chem 1999; 274:11897-11903.
25. Deckmyn H, Chew SL, Vermylen L. Lack of platelet response to collagen associated with antibody against GpIa: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost 1990; 64:74-79.
26. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two neutral polymorphism in the alpha 2 gene coding sequence. Blood 1997; 89:1939-1943.
27. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki T. Nucleotide polymorphisms in the alpha 2 gene define multiple alleles that are associated with differences in platelet alpha 2 beta 1 density. Blood 1998; 92:2382-2388.
28. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of platelet GP Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93:2449-2453.
29. Moshfegh K, Wuillemin WA, Redondo M. Association of two silent polymorphism of platelet GP Ia/IIa receptor with risk of myocardial infarction. Lancet 1999; 353:351-354.
30. Corral L, Gonzales R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807C/T polymorphism of the alpha 2 gene in platelet GP Ia collagen receptor expression and function: effect in thromboembloic diseases. Thromb Haemost 1999; 81:951-956.
31. Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ. The GP Ia C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106:771-776.
32. Beckerath N, Koch W, Mehilli J, Bottiger C, Schomig A, Kastrati A. GP Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary stenting. Blood 2000; 95:3297-3301.
33. Jandrot-Perrus M, Busfield S, Lagrue A, Xiong X, Debili N, Chickering T. Cloning, characterization, and functional studies of human and mouse GP VI: a platelet specific collagen receptor from the Ig superfamily. Blood 2000; 96:1798-1807.
34. Kehrel B, Wierwille S, Clemetson K, Anders O, Steiner M, Knight C. GP VI is a major collagen receptor for platelet activation: it recognizes the platelet activating quaternary structure of collagen, whereas CD36, GP IIb/IIIa, and vWF do not. Blood 1998; 91:491-499.
35. Knight CG, Morton LF, Onley DJ, Peachey AR, Ichinohe T, Okuma M. Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet GP VI and mediates platelet activation by collagen. Cardiovasc Res 1999; 41:450-457.
36. Thiagarajan P, Tait JF. Collagen induced exposure of anionic phospholipids in platelets and platelet-derived microparticles. J Biol Chem 1991; 266:24302-24307.
37. ++ responses. Blood 1997; 90:2615-2625.
38. Furihata K, Clemetson KJ, Deguchi H, Kunicki TJ. Variation in human platelet GP VI content modulates GP VI specific prothrombinase activity. Arterioscler Thromb Vasc Biol 2001; 21:1857-1863.
39. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, et al. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 2001; 104:1459-1463.
40. Born GV. Aggregation of blood platelets by ADP and its reversal. Nature 1962; 194:927-928.
41. Rao AK. Congenital disorders of platelet function. Platelets in health and disease. Hematol Oncol Clin North Am 1990; 4:65-82.
42. Mills D. ADP receptors on platelets. Thromb Haemost 1997; 76:835-856.
43. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP induced platelet activation, I: evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273:2024-2029.
44. Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets. J Biol Chem 1998; 273:11544-11547.
45. Savi P, Beaverger P, Labouret C, Delfaud M, Salel V, Kaghad M, et al. Role of P2Y1 purinoceptor in ADP induced platelet activation. FEBS Lett 1998; 422:291-295.
46. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409:145-147.
47. CAPRIE steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996; 348:1329-1339.
48. CURE investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
49. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction 2002: summary article: a report of the ACC/AHA task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002; 106:1893-1900.
50. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J Clin Invest 1999; 104:1731-1737.
51. Leon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C, et al. Key role of the P2Y1 receptor in tissue factor induced thrombin dependent acute thromboembolism. Studies in P2Y1 knockout mice and mice treated with a P2Y1 antagonist. Circulation 2001; 103:718-723.
52. Van Willigen G, Akkerman JW. Regulation of GP IIb/IIIa exposure on platelets stimulated with alpha thrombin. Blood 1992; 79:82-90.
53. Glusa E. Vascular effects of thrombin. Semin Thromb Hemost 1992; 18:296-304.
54. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394:690-694.
55. Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P. Unique pathway of thrombin-induced platelet aggregation mediated by GP Ib. J Biol Chem 2001; 276:21173-21183.
56. Chessbro JH, Zoldhelyi P, Fuster V. Pathogenesis of thrombosis in unstable angina. Am J Cardiol 1991; 17:96B-100B.
57. Kahn ML, Nakanish-Mutsuim M, Shapiro MJ, Ishihara H, Conghlin SR. PAR-I and 4 mediates activation of human platelets by thrombin. J Clin Invest 1999; 103:879-887.
58. Furman MI, Liu I, Benoit S, Becker RC, Barnard MR, Michelson AD, et al. The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci USA 1998; 95:3082-3087.
59. Anderson H, Greenberg D, Fujikawa K, Xu W, Chung DW, Davie EW, et al. Protease activated receptor-1 is the primary mediator of thrombin stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96:11189-11193.
60. Ramakrishnan V, Deguzman F, Bao M, Hall SW, Leung LL, Phillips D, et al. A thrombin receptor function for platelet GP Ib-IX unmasked by cleavage of GP V. Proc Natl Acad Sci USA 2001; 98:1823-1828.
61. De Marco L, Mazzucato M, Masotti A, Fenton JW, Ruggeri ZM. Function of GP Iba in platelet activation induced by alpha thrombin. J Biol Chem 1991; 226:23776-23783.
62. Dormann D, Clemetson K, Kehrel B. The GP Ib thrombin-binding site is essential for thrombin induced platelet procoagulant activity. Blood 2000; 96:2469-2478.
63. Zhou Q, Zhou J, Stout JG, Luhm RA, Wiedmer T, Sims PJ. Molecular cloning of human membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phosoholipids. J Biol Chem 1997; 272:18240-18244.
64. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochem Biophys Acta 1983; 736:57-66.
65. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 1995; 74:962-968.
66. Bevers EM, Comfurius P, Van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122:429-436.
67. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265:17420-17423.
68. Fox JE, Austin CD, Reynolds CC, Steffen PK. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266:13289-13295.
69. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995; 75:12B-17B.
70. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74:1-23.
71. Weitz JL, Hudoba M, Massell D, Maraganore J, Hirsh J, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by anti-thrombin independent inhibitors. J Clin Invest 1990; 86:385-391.
72. Maraganore J. Pre-clinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor. In: Claeson G, Scully M, Kakkar V, Deadman J, editors. Design of synthetic inhibitors of thrombin. New York: Plenum Press; 1993. pp. 227-236.
73. OASIS investigators. Comparison of hirudin with heparin and warfarin for control of unstable angina and non-Q wave myocardial infarction in a randomized controlled trial. Circulation 1995; 92:1-416.
74. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina: results of the thrombin inhibition in myocardial ischemia (TIMI) 7 trial. Circulation 1995; 92:727-733.
75. Van Den Boss AA, Deckers JW, Laarman GJ, Suryapramata H, Zijlstra F. Safety and efficacy of recombinant hirudin versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88:2058-2066.
76. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman A, et al. Use of a direct anti-thrombin hirulog in place of heparin during coronary angioplasty. Circulation 1993; 87:1622-1629.
77. Serruys PW, Herrman J-pr, Simon R, Rutsch W, Bode C, Laarman J, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333:757-764.
78. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI 9a) trial. Circulation 1994; 90:1624-1630.
79. GUSTO IIa investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 60:1631-1637.
80. Antman EM. Hirudin in acute MI. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI 9b) trial. Circulation 1996; 94:911-921.
81. Topol EJ, GUSTO IIb investigators. A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335:775-782.
82. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, et al. Hirudin interruption of heparin resistant arterial thrombus formation in baboons. Blood 1991; 77:1006-1012.
83. Klement P, Liao P, Hirsh J, Johnston M, Weitz JI, et al. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med 1998; 132:181-185.
84. Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91:1568-1574.
85. White HD, Aylward PE, Frey JJ, Adgey AAJ, Nair R, Hillis WS, et al. A randomized, double blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96:2155-2161.
86. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82:12P-18P.
87. Du XP, Plow EF, Frelinger AL, O'Toole TE, Loftus JC, Ginsberg MH, et al. Ligands activate integrin GP IIb/IIIa. Cell 1991; 65:409-416.
88. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998; 97:5-9.
89. Topol EJ, Byzova TV, Plow EF. Platelet GP IIb/IIIa blockers. Lancet 1999; 353:227-231.
90. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab demonstrates equivalent affinity and functional blockade of GP IIb/IIIa and alpha v beta 3 integrins. Circulation 1998; 98:1085-1091.
91. Coller BS. Potential non GP IIb/IIIa effects of abciximab. Am Heart J 1999; 138:S1-S5.
92. Topol EJ, Moliterno DJ, Herrmann HC, Powers E, Grines C, Cohen D, et al. Comparison of two platelet GP IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revacularization. N Engl J Med 2001; 344:1888-1894.
93. Kabbani SS, Aggarwal A, Terrien E, Dibattiste PM, Sobel BE, Schneider D, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89:647-650.
94. Gurbel PA, Serebruany VL. Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. J Thromb Thrombol 2000; 10:217-220.
95. Chew DP, Bhatt D, Sapp S, Topol EJ. Increased mortality with oral platelet GP IIb/IIIa antagonist: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103:201-206.
96. Serebruany VL, Malinin A, O'Connor CM, Gurbel P. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary disease [abstract]. Eur Heart J 2002; 23:640.
97. Bottiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schomig K. HPA-1 and HPA-3 polymorphism of the platelet fibrinogen receptor and coronary artery disease and MI. Thromb Haemost 2000; 83:559-562.
98. Bottiger C, Kastrati A, Koch W, Mehilli J, von Beckerath N, Dirschinger J, et al. Polymorphism of platelet GP IIb and risk of thrombosis and restenosis after coronary stent placement. Am J Cardiol 1999; 84:987-991.
99. Weiss EJ, Bray PF, Tayback M, Schulman S, Kickler T, Becker L, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334:1090-1094.
100. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet GP IIIa polymorphism and risk of coronary stent thrombosis. Lancet 1997; 350:1217-1219.
101. Ridker P, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet GP IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349:385-388.
102. Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz PM. A1/A2 polymorphism of GP IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999; 353:708-712.
103. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94:1239-1246.
104. PARAGON investigators. International, randomized, controlled trial of lamifiban, heparin, or both in unstable angina. Circulation 1998; 97:2386-2395.
105. PRISM study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505.
106. PRISM-PLUS study investigators. Inhibition of the platelet GP IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave MI. N Engl J Med 1998; 338:1488-1497.
107. PURSUIT trial investigators. Inhibition of platelet GP IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-443.
108. GUSTO IV-ACS investigators. Effect of GP IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndrome without early coronary revascularisation: the GUSTO IV-ACS trial. Lancet 2001; 357:1915-1924.
109. Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT. Flow cytometry reveals activated GP IIb/IIIa complexes on platelet from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinol 1995; 6:395-410.
110. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol EJ. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998; 31: 1466-1473.
111. GUSTO V investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet GP IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 2001; 357:1905-1914.
112. Dalby MC, Davidson SJ, Burman JF, Sigwart U, Davies SW. Abciximab is rapidly effective in preventing and arresting established platelet aggegation. J Thromb Thrombol 2002; 13:141-145.
113. Neumann FJ, Ott I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27:819-824.
114. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94:279-285.
115. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany V, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting (The PRONTO trial). Am Heart J (in press).
116. EPIC investigators. Use of monoclonal antibody directed against the platelet GP IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961.
117. EPILOG investigators. Platelet GP IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689-1696.
118. CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349:1429-1435.
119. IMPACT-II investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997; 349:1422-1428.
120. RESTORE investigators. Effects of platelet GP IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.
121. EPISTENT investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet GP IIb/IIIa blockade. Lancet 1998; 352:87-92.
122. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 5:864-868.
123. Topol EJ, Califf RM, Weisman HF. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical re-stenosis: results at 6-months. Lancet 1994; 343:881-886.
124. 3 receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit [abstract]. Circulation 2001; 103:1906-1911.
125. 3 and osteopontin expression during neointima formation. Cardiovas Res 1997; 36:408-428.
126. 3 on platelets and lymphocytes binds to the matrix protein osteopontin. J Biol Chem 1997; 272:8137-8140.
127. 3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998; 143:2081-2092.
128. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS, et al. Inhibition of platelet mediated, tissue factor induced, thrombin generation by the mouse/human chimeric 7E3 antibody; potential implication for the effect of c7E3 Fab treatment on acute thrombosis and clinical restenosis. J Clin Invest 1996; 98:863-874.
129. Li Y, Spencer FA, Becker RC. Synergistic effects of GPIIb/IIIa antagonists and heparin on platelet dependent procoagulant activity and thrombin generation. Circulation 1999; 100 [abstract-suppl]:1-303.
130. 3 in vascular biology. Thromb Haemost 1998; 80:726-734.
131. Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, et al. Vitronectin receptor mediates platelet adhesion to the luminal aspect of endothelial cells. Circulation 1997; 96:1809-1818.
132. D'Souza SE, Byers-Ward F, Plow EF. Fibrinogen bridges platelets to endothelial cells. FASEB J 1994; 8:A 267.
133. 3 for angiogenesis. Science 1994; 264:569-571.
134. 3 integrins are upregulated after vascular injury and modulate thrombospondin and thrombin induced proliferation of cultured smooth muscle cells. Circulation 1998; 97:907-915.
135. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neo-intimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253:1129-1132.
136. Liu MW, Roubin GS, Robinson KA, Black AJ, Hearn JA, Siegel RJ, et al. Trapidil in preventing re-stenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 1990; 81:1089-1093.
137. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999; 340:115-126.
138. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in active coronary artery disease. Am J Cardiol 1990; 65:168-172.
139. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic disease. JAMA 1987; 257:2318-2324.
140. Lowe GDO, Machado SG, Krol WF, Barton BA, Forbes CD. White blood cell count and hematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985; 54:700-703.
141. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159-163.
142. Gurbel P, Kolodgie F, Serebruany V, Mergner W. Myocardial cell injury during ischemia and reflow. In: Bittar E, Bittar N, editors. Principles of medical biology. Stamford, Connecticut: JAI Press; 1998. pp. 127-166.
143. Furie B, Furie BC, Flaumenhaft R. A journey with p-selectin: the molecular basis of granule secretion, signaling and cell adhesion. Thromb Haemost 2001; 86:214-221.
144. Moore KL, Patel KD, Bruehl RE, Li F, Johnson DA, Lichenstein HS, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophil on P-selectin. J Cell Biol 1995; 128:661-671.
145. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20:2322-2328.
146. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C. Induction of cytokine expression in leukocytes by binding of thrombin stimulated platelets. Circulation 1997; 95:2387-2394.
147. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of GP IIb/IIIa receptor blockade on platelet leukocyte interaction and surface expression of the leukocyte integrin MAC-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34:1420-1426.
148. Koichi K, Hisao O, Hirofumi Y, Tomohiro S, Hisakazu S, Hitoshi S, et al. Soluble p-selectin is released into the coronary circulation after coronary spasm. Circulation 1995; 92:1726-1730.
149. Ikeda H, Takajo Y, Ichiki K, Ueno T, Maki S, Noda T, et al. Increased soluble form of p-selectin in patients with unstable angina. Circulation 1995; 92:1693-1696.
150. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 2000; 36:1210-1216.
151. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface p-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104:1533-1537.
152. Gurbel P, Kereiakes D, Dalesandro M, Bahr RD, O'Connor CM, Serebruany VL. Role of soluble and platelet bound p-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department. Am Heart J 2000; 139:320-328.
153. Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Shomig A, et al. Role of activation dependent platelet membrane GP in development of subacute occlusive coronary stent thrombosis. Coronary Artery Dis 1997; 8:121-128.
154. Gurbel P, Serebruany V, Shustov A, Dalesandro M, Gumbs CI, Grablutz et al. Increased baseline levels of platelet p-selectin and platelet endothelial adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. Coronary Artery Dis 1998; 9:451-456.
155. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of pre-existing statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 2001; 87:446-448.
156. Ferns GA, Forster LA, Williams JC, Tull SP, Verma PK, Starkey B. Effects of vitamin E supplementation on circulating cell adhesion molecules pre- and post PTCA. Ann Clin Biochem 2000; 37:649-654.
157. Gawaz M. Antithrombocytic effectiveness of magnesium. Fortschr Med 1996; 114:329-332.
158. Nagashima M, Shin Oka T, Nollert G. Effects of monoclonal antibody to p-selectin on recovery of neonatal lamb hearts after cold cardioplegic ischemia. Circulation 1998; 98(suppl 19):II391-II397.
159. Norman KE, Katopodis AG, Thoma G, Kolbinger F, Hicks A, Cotter M, et al. PSGL-1 supports rolling on e-selectin and p-selectin in vivo. Blood 2000; 96:3585-3591.
160. Walcheck B, Moore KL, McEver RP, Kishimoto KT, et al. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve I-selectin and PSGL-1: a mechanism that amplifies initial leukocyte accumulation on p-selectin in vitro. J Clin Invest 1996; 98:1081-1087.
161. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM, et al. Recombinant soluble PSGL-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41:65-76.
162. Bienvenu JG, Tanguay JF, Theoret JF, Kumar A, Schaub RG, Merhi Y, et al. Recombinant PSGL-1 Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation 2001; 103:1128-1134.
163. Theoret JF, Bienvenu JG, Kumar A, Merhi Y. P-selectin antagonism with rPSGL-Ig inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther 2001; 298:658-664.
164. Sarma J, Laan C, Alam S, Jha A, Fox KAA, Dransfield I, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105:2166-2171.
165. Weber C, Springer TA. Neutrophil accumulation on activated, surface adherent platelet in flow is mediated by interaction of MAC-1 with fibrinogen bound to GP IIb/IIIa and stimulated by platelet activating factor. J Clin Invest 1997; 100:2085-2093.
166. Meisel S, Shapiro H, Radnay J, Neuman Y, Khaskia AR, Gruener N, et al. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and MAC-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction. J Am Coll Cardiol 1998; 31:120-125.
167. Kassirer M, Zeltser D, Prochorov V, Schoenman G, Frimerman A. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. Am Heart J 1999; 138:555-559.
168. Mickelson J, Lakkis N, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease. J Am Coll Cardiol 1996; 28:345-353.
169. Mickelson JK, Ali N, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ. Reopro decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 33:97-106.
170. Simpson PJ, Todd RD, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988; 81:624-629.
171. Faxon D, Gibbons R, Chronos N, Gurbel P, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT MI study. J Am Coll Cardiol 2002; 40:1199-1204.
172. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, et al. Double-blind, randomized trial of an anti-CD 18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104:2778-2883.
173. Diacovo TG, Defougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 1994; 94:1243-1251.
174. Kuijper PHM, Gallardo Torres HI, Lammers WJ, Sixma JJ, Koenderman L, Zwagina JJ. Platelet associated fibrinogen and ICAM-2 induce firm adhesion of neutrophils under flow conditions. Thromb Haemost 1998; 80:443-448.
175. Newman PJ, Berndt MC, Gorsky J, White GC, Lyman S, Paddock C. PECAM-1 cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990; 247:1219-1222.
176. Serebruany VL, Gurbel PA. Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 in patients with acute MI. Arterioscler Thromb Vasc Biol 1999; 19:153-158.
177. Gumina RJ, Schultz JE, Yao Z, Kenny D, Warltier DC, Newman PJ. Antibody to PECAM-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. Circulation 1996; 94:3327-3333.
178. Serebruany VL, Murugesan SR, Pothula A, Semaan H, Gurbel P. Soluble PECAM-1, but not p-selectin nor osteonectin identify acute myocardial infarction in patients presenting with chest pain. Cardiology 1999; 91:50-55.
179. Serebruany VL, Murugesan SR, Pothula A, Atar D, Lowry DR, O'Connor CM. Increased soluble PECAM-1 and osteonectin levels in patients with sever congestive heart failure, independence of disease etiology and antecedent aspirin therapy. Eur J Heart Fail 1999; 1:243-249.
180. Henn V, Slupsky JS, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 351:591-594.
181. Hermann A, Rauch BH, Braun M, Schror K, Weber AA, et al. Platelet CD40 ligand sub-cellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12:74-82.
182. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications7 for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94:1931-1936.
183. Slupsky J, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80:1008-1014.
184. Mach F, Schonbeck U, Bonefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Circulation 1997; 96:396-399.
185. Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry M. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156:7-14.
186. Garlichs CD, John S, Schmeiber A, Eskafi S, Stumpf C, Karl M, et al. Upregulation of CD40 and CD40 ligand in patients with moderate hypercholesterolemia. Circulation 2001; 104:2395-2400.
187. Cipollone F, Mezzeti A, Porreca E, Febbo CD, Nutini M, Fazia M. Association between enhanced soluble CD40 ligand and prothrombotic state in hypercholesterolemia, effects of statin therapy. Circulation 2002; 106:399-402.
188. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hymes RO. CD40 ligand stabilizes arterial thrombi by a beta 3 integrin dependent mechanism. Nature Medicine 2002; 8:247-252.
189. Nannizzi-Alaimo L, Alves V, Srinivasa K, Stockett DE, Phillips DR. GP IIb/IIIa antagonists demonstrate a dose dependent inhibition and potentiation of soluble CD40 ligand release during platelet stimulation. Circulation 2001; 104:II-318.
190. Aukrust P, Muller F, Ueland T, Bergert T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane bound CD40 ligand in patients with unstable angina. Circulation 1999; 100:614-620.
191. Lee Y, Lee WH, Lee SC, Ahn K, Choi Y, Park S. CD40 ligand activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999; 92:11-16.
192. Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86:649-655.
193. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000; 97:7458-7463.